The Biology and Genetics of ATP13A2

To understand ATP13A2-related disorders, it helps to look deep inside your cells at a gene called ATP13A2. This gene acts like an instruction manual for a protein that manages the “recycling center” of your cells, known as the lysosome ^[1]. When this gene contains pathogenic variants, the recycling system breaks down, leading to the symptoms of the disease.

The Biological “Recycling Failure”

Laboratory models suggest the ATP13A2 protein is a “pump” that lives on the surface of the lysosome. Its main job is believed to be moving substances called polyamines (specifically one called spermine) out of the lysosome and into the rest of the cell ^[1][2].

When the gene has a pathogenic variant, altered protein function means this pump fails in models, which research suggests causes several biological “traffic jams”:

• Waste Accumulation: Polyamines may build up inside the lysosome, making it unstable. Eventually, the lysosome may rupture, leaking harmful digestive enzymes into the cell ^[1][3].
• Lipofuscin Buildup: The cell may no longer clear away a fatty, pigmented waste material called lipofuscin. This buildup is why the condition is sometimes called a Neuronal Ceroid Lipofuscinosis (NCL) ^[3][4].
• Energy Stress: Because the recycling system is broken, the cell cannot properly dispose of damaged “powerhouses” (mitochondria), which causes the cell to become stressed and eventually stop working correctly ^[5][6].
  Note that these mechanisms are largely based on cell and animal studies and remain an active area of research.

How the Condition is Inherited

This condition follows a pattern called autosomal recessive inheritance ^[6]. This means that for a person to have the disease, they must inherit two copies of the altered ATP13A2 gene—one from their mother and one from their father ^[7].

• Carriers: Parents are typically “carriers.” They have one working gene and one altered gene. Carriers usually have no symptoms because their one working gene provides enough protein for the cell’s recycling center to function ^[8].
• The 25% Rule: When two carriers have a child, there is a 25% (1 in 4) chance with each pregnancy that the child will inherit both altered genes and have the condition, a 50% chance the child will be a carrier like the parents, and a 25% chance the child will inherit two working genes ^[7][8]. For an adult who already has the condition, the risk to their future children depends on the partner’s carrier status. Genetic counseling is highly recommended to explore cascade testing.

The Path to a Definitive Diagnosis

While a doctor may suspect the condition based on symptoms, a definitive diagnosis of ATP13A2-related disease is confirmed through genetic testing ^[8].

To receive a molecular confirmation, testing must identify pathogenic or likely pathogenic biallelic variants. This means there are two confirmed disease-causing changes in the ATP13A2 gene, demonstrated or strongly supported to be on opposite alleles (in trans) ^[6]. Two variants of uncertain significance, or only one variant, do not establish the diagnosis. These changes can be:

1. Homozygous: The exact same mutation is inherited from both parents ^[8].
2. Compound Heterozygous: Two different mutations are found in the ATP13A2 gene, one from each parent ^[7].

Doctors often use multigene panels, targeted testing, or Whole Exome Sequencing (WES) or Whole Genome Sequencing (WGS), which look at thousands of genes at once to find the specific variants in the ATP13A2 gene ^[7][9].

What Brain Imaging Shows

Your doctor may order an MRI (Magnetic Resonance Imaging) to look at the structure of the brain. While an MRI cannot diagnose the disease on its own, it provides “supportive evidence” that helps confirm what the genetic test finds ^[10].

Common findings reported in some individuals on an MRI with an ATP13A2-related condition include:

• Atrophy: This is a medical term for “shrinking.” It often affects the cerebellum (the part of the brain that controls balance) and the cerebrum (the part involved in thinking and movement) ^[10][6].
• Thin Corpus Callosum: The bridge of tissue that connects the two halves of the brain may appear thinner than usual ^[11].
• Iron Accumulation: In some cases, the MRI may show an unusual buildup of iron in the basal ganglia, a group of structures deep in the brain that control movement. Because of this, ATP13A2 is sometimes grouped with conditions known as NBIA (Neurodegeneration with Brain Iron Accumulation) ^[12][13], but iron accumulation is not present in everyone and this condition is often an occasional phenocopy rather than a classic NBIA condition.

It is important to remember that some people with the disease will have a completely normal MRI, especially in the early stages, so a normal MRI does not exclude the disorder, and an abnormal MRI is not diagnostic. This is why genetic testing remains the “gold standard” for diagnosis ^[10][8].